ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
 PMID: 34897227       2022       Journal of acquired immune deficiency syndromes (1999)
Abstract: Studies have demonstrated safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), including in patients with M184V/I substitutions.
Introduction: This efficacy also extends to VS patients with certain nucleos(t)ide reverse transcriptase inhibitor (NRTI) substitutions, including M184V/I and thymidine analog substitutions.
Table: M184V/I


  Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
 PMID: 34694877       2022       Antimicrobial agents and chemotherapy
Result: One participant (participant 1) had the integrase substitution R263R/K and NRTI resistance-associated substitutions K65R and M184I/V at baseline, despite no apparent prior INSTI treatment, but did not demonstrate in vitro dolutegravir phenotypic resistance.
Table: M184I/V
Discussion: Unusually, 1 participant had the highly conserved integrase substitutions R263R/K and M184I/V as mixtures at baseline but not at CVW.


  Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
 PMID: 34741609       2022       The Journal of antimicrobial chemotherapy
Result: All participants with K65R also had M184I/V.
Result: There was also a high prevalence of mutations among the 12 participants who were sampled less than 1 year after initiating first-line treatment: 6 (50%) had TAMs present at >=2% frequency; 10 (83%) had core NRTI mutations (of which all 10 had M184IV and 7 also had other core NRTI mutations); and 12 (100%) had NNRTI mutations.
Discussion: Notably, all participants in the present analysis who had the K65R mutation also had M184I/V.


  Diversity of HIV-1 Subtypes and Transmitted Drug-resistance Mutations Among Minority HIV-1 Variants in a Turkish Cohort.
 PMID: 34802406       2022       Current HIV research
Abstract: M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS.


  Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
 PMID: 34849981       2022       The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Lamivudine/dolutegravir maintenance DT showed similar efficacy to dolutegravir-based TT; however, past M184V/I may favour VF.
Abstract: Conversely, in the setting of pre-existing M184V/I, DT showed a trend to increased risk of VF (versus tenofovir-based TT, aHR = 137.50, 95% CI = 4.24-4464.06; versus abacavir-based TT, aHR = 33.88, 95% CI = 1.75-656.47).


  Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
 PMID: 34871089       2022       Antimicrobial agents and chemotherapy
Result: In addition, K65R plus Y115F (n = 1) and M184I (n = 2) were observed in combination with RPV RAMs.


  Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
 PMID: 34873084       2022       AIDS (London, England)
Result: Among those harbouring a M184 V/I mutation, no differences between reported PrEP intake (daily vs.
Table: M184V/I
Discussion: At least two-thirds of those carrying a M184V/I mutation in our cohort acquired HIV recently, with a large majority reporting sub-optimal PrEP adherence, irrespectively of the PrEP scheme adopted, confirming the trend observed previously in our cohort and in other reports.


  Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
 PMID: 35192922       2022       Journal of clinical epidemiology
Abstract: Patients failing first-line ART including emtricitabine or lamivudine showed high levels of the M184V/I mutation after two years: 75.7% (95% Credibility Interval [CrI] 61.9%-88.9%) if combined with tenofovir, and 72.1% (95% CrI 56.8%-85.9%) with zidovudine.


  Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.
 PMID: 35164871       2022       Journal of medical case reports
Discussion: Cerebrospinal fluid escape is seen after more than 15 years of HIV infection, previous low-level viremia, and the presence of M184V/I mutations in the CSF.


  Prevalence of transmitted drug resistance among ART-naive HIV-infected individuals, Beijing, 2015-2018.
 PMID: 35092830       2022       Journal of global antimicrobial resistance
Abstract: The thymidine analogue mutations (TAMs) M41L/LM (4, 0.12%) and non-TAMs mutations M184V/MV/MI (8; 0.24%) were the primary NRTI-associated resistance mutations.



Browser Board

 Co-occurred Entities




   Filtrator